Cargando…

Young patients show poor efficacy for immune checkpoint inhibitor combined therapy in metastatic gastrointestinal cancers

BACKGROUND: The impact of age on the efficacy and safety of immunotherapy remains controversial. The previous studies simply classified patients into younger and older groups, which might not reflect the real impact of young age on immunotherapy efficacy. The current study aimed to explore the effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yingnan, Zhang, Shasha, Zhang, Fengbin, Wang, Lei, Wu, Chensi, Zhang, Xiaoyun, Zhang, Ruixing, Guo, Zhanjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189879/ https://www.ncbi.nlm.nih.gov/pubmed/37207161 http://dx.doi.org/10.3389/fonc.2023.1155019

Ejemplares similares

Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients
por: Zhao, Yue, et al.
Publicado: (2022)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Yue, et al.
Publicado: (2022)

Single nucleotide polymorphisms in the mitochondrial displacement loop and outcome of esophageal squamous cell carcinoma
por: Zhang, Ruixing, et al.
Publicado: (2010)

Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review
por: Geng, Dandan, et al.
Publicado: (2022)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Identification of sequence polymorphism in the D-Loop region of mitochondrial DNA as a risk factor for hepatocellular carcinoma with distinct etiology
por: Zhang, Ruixing, et al.
Publicado: (2010)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
por: Jo, Hyunji, et al.
Publicado: (2022)

Identification of polymorphisms in mitochondrial cytochrome c oxidase genes as risk factors for gastric cancer
por: Wang, Yingnan, et al.
Publicado: (2020)

The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small Cell Lung Cancer: A Meta-Analysis
por: Li, Sihan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
por: Kamath, Suneel D., et al.
Publicado: (2018)

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report
por: Wu, Xiaoli, et al.
Publicado: (2020)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors
por: Pan, Shen, et al.
Publicado: (2019)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
por: Jiang, Shuai, et al.
Publicado: (2022)

Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
por: Xia, Handai, et al.
Publicado: (2022)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Liao, Juan-Yan, et al.
Publicado: (2021)

Case Report: Immune Checkpoint Inhibitors as a Single Agent in the Treatment of Metastatic Cervical Cancer
por: Anipindi, Manasa, et al.
Publicado: (2022)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
por: Fernandez, Elvelyn R., et al.
Publicado: (2023)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
por: Zhu, Shicong, et al.
Publicado: (2020)

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
por: Bai, Jing, et al.
Publicado: (2022)

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
por: Rolles, Benjamin, et al.
Publicado: (2021)

Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors
por: Young, Richard Benjamin, et al.
Publicado: (2022)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Association of Brain Metastases With Immune Checkpoint Inhibitors Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis
por: Wang, Yanning, et al.
Publicado: (2021)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Antibiotics Modulate Chemotherapy Efficacy in Patients with Esophageal Cancer
por: Wu, Chensi, et al.
Publicado: (2020)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma
por: Li, Ying, et al.
Publicado: (2022)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ekv93uhvtruik033c4ot5hqjha